Innovent Biologics (STU:6IB) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:6IB Innovent Biologics Inc STU:6IB
80 GF Score
Price €10.10
GF Value €11.08
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Innovent Biologics Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:6IB
80GF Score
Innovent Biologics Inc STU:6IB
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Innovent Biologics (STU:6IB) Overvalued in 2026?

Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued. The current stock price of €10.10 is trading 8.8% below its estimated GF Value™ of €11.08. GuruFocus considers Innovent Biologics to be Fairly Valued.

Key valuation signals for STU:6IB:

  • Dividends Received:
  • GF Value™: €11.08 vs. price of €10.10 (8.8% below fair value)
  • GF Score™: 80/100 with 2 warning signs

No single metric tells the full story. See the STU:6IB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Innovent Biologics Business Description

Address 168 Dongping Street, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215123
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
80GF Score

Get the complete analysis for STU:6IB

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.10
Price
€11.08
GF Value